Akoya Biosciences (Akoya Biosciences) Cash Flow from Financing : $56.82 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Akoya Biosciences Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2024, Akoya Biosciences paid $0.00 Mil more to buy back shares than it received from issuing new shares. It spent $0.18 Mil paying down its debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It spent $0.26 Mil on other financial activities. In all, Akoya Biosciences spent $0.44 Mil on financial activities for the three months ended in Mar. 2024.

Akoya Biosciences Cash Flow from Financing Historical Data

The historical data trend for Akoya Biosciences's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akoya Biosciences Cash Flow from Financing Chart

Akoya Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow from Financing

28.56

5.49

137.04

28.73

56.84

Akoya Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash Flow from Financing	Get a 7-Day Free Trial													-0.42	46.33	-0.14	11.08	-0.44

Akoya Biosciences Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Akoya Biosciences's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

	Cash Flow from Financing		(A: Dec. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	47.967	+	0	+	10.574	+	0	+	0	+	-1.697
=	56.84

Akoya Biosciences's Cash from Financing for the quarter that ended in Mar. 2024 is:

	Cash Flow from Financing		(Q: Mar. 2024 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	-0.181	+	0	+	0	+	-0.263
=	-0.44

Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $56.82 Mil.

Akoya Biosciences (NAS:AKYA) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Akoya Biosciences's issuance of stock for the three months ended in Mar. 2024 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Akoya Biosciences's repurchase of stock for the three months ended in Mar. 2024 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Akoya Biosciences's net issuance of debt for the three months ended in Mar. 2024 was $-0.18 Mil. Akoya Biosciences spent $0.18 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Akoya Biosciences's net issuance of preferred for the three months ended in Mar. 2024 was $0.00 Mil. Akoya Biosciences paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Akoya Biosciences's cash flow for dividends for the three months ended in Mar. 2024 was $0.00 Mil. Akoya Biosciences received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Akoya Biosciences's other financing for the three months ended in Mar. 2024 was $-0.26 Mil. Akoya Biosciences spent $0.26 Mil on other financial activities.

Akoya Biosciences Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Akoya Biosciences's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Akoya Biosciences (Akoya Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Akoya Biosciences Inc (NAS:AKYA) » Definitions » Cash Flow from Financing

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Campus Drive, 6th Floor, Marlborough, MA, USA, 01752

Website

https://www.akoyabio.com

Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery and clinical research. The company offers the comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications. The company has its geographical presence in North America, APAC and EMEA. It generates majority of the revenue from North America.

Executives

Brian Mckelligon	director, officer: President/CEO	100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Frederic Pla	officer: Chief Operating Officer	C/O GENOMIC HEALTH, INC., 101 GALVESTON DRIVE, REDWOOD CITY CA 94063-4700
Goldman Myla Lai	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
John Frederick Ek	officer: Chief Financial Officer	5964 LA PLACE COURT, CARLSBAD CA 92008
Scott Mendel	director	5964 LA PLACE COURT, ADDRESS 2, CARLSBAD CA 92008
Matthew Winkler	director	C/O MIRNA THERAPEUTICS, INC., 2150 WOODWARD ST., SUITE 100, AUSTIN TX 78744
Thomas A. Raffin	director, 10 percent owner	C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AIMES IA 50010
Robert G Shepler	director
Jennifer Kamocsay	officer: General Counsel	100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01762
Joseph Driscoll	officer: Chief Financial Officer	5 DICARLO ROAD, HOPKINTON MA 01748
Nolan Garry Ph.d.	director	100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Thomas P Schnettler	director	800 NICOLLET MALL, J1012057, MINNEAPOLIS MN 55402-7020
Ehab El-gabry	officer: Chief Medical Officer	100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Marilee Moy	officer: Chief People Officer	100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Ramachandran Niro Ph.d	officer: Chief Business Officer	100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752